AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2026
Jan 22, 2026
31523_dirs_2026-01-22_6aebf7fe-f669-4738-ae8d-a8b282898a96.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2026-01-20
Reporting Person: Campbell Bradley L (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-01-20 | Common Stock | M | 75000 | $6.10 | Acquired | 1096180 | Direct |
| 2026-01-20 | Common Stock | S | 75000 | $14.3091 | Disposed | 1021180 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-01-20 | Stock Options (right to buy) | $6.10 | M | 75000 | Disposed | 2026-06-15 | Common Stock (75000) | Direct |
Footnotes
F1: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.30 to $14.32 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: All of the options were fully vested and exercisable as of the transaction date.